Gefitinib Krka

Gefitinib Krka is an oral medication used for targeted therapy in certain types of cancer. This pharmaceutical is designed to inhibit specific proteins that contribute to cancer cell growth.

Gefitinib Krka is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic markers. It works by targeting epidermal growth factor receptor (EGFR) mutations, which are found in some cancer cells. This medication is part of a class of drugs known as tyrosine kinase inhibitors, which help to slow or stop the growth of cancer cells.

Common effects of Gefitinib Krka may include skin rash, diarrhea, and appetite loss. Some users might experience dry skin, nausea, or fatigue. These effects can vary in severity and may not affect everyone who takes the medication.

Gefitinib Krka should be handled with care and stored as directed. It is important to follow the advice of a healthcare professional regarding its use. This medication may not be suitable for everyone, especially those with certain medical conditions or allergies.

Gefitinib Krka may interact with other medications, including certain antibiotics, antifungals, and seizure medications. It is important to inform a healthcare professional about all medications being taken to avoid potential interactions. Additionally, grapefruit and grapefruit juice should be avoided as they can affect how the body processes Gefitinib.